CHICAGO – April 28–29, 2025 – EG BioMed, a biotechnology company specializing in early cancer detection using methylated circulating cell-free DNA, today announced that it will present three scientific abstracts at the upcoming American Association for Cancer Research® (AACR) Annual Meeting 2025. These studies highlight the use of DNA methylation biomarkers for non-invasive cancer detection and early screening applications.
Full List of EG BioMed Presentations
- Poster #3677, Section 46, Board #6 — Pancreatic Cancer Blood Test
- Poster #LB256, Section 51, Board #5 — Breast Cancer Blood Test
- Poster #4554, Section 29, Board #7 — Colorectal Cancer Blood Test
| Title | Poster | Product |
|---|---|---|
| April 28, 2025, 2:00–5:00 PM Early detection of pancreatic cancer using methylated circulating cell-free DNA of ZFP30 and ZNF781 genes | Section 46, Board #6 | Pancreatic Cancer Blood Test (Available in the U.S.) |
| April 29, 2025, 9:00 AM–12:00 PM Circulating methylated GCM2 and TMEM240 as novel biomarkers for dynamic monitoring of breast cancer progression and treatment response | Section 51, Board #5 | Breast Cancer Blood Test (Coming Soon) |
| April 29, 2025, 9:00 AM–12:00 PM Advanced detection of TMEM240 hypermethylation in circulating cell-free DNA as a novel biomarker for colorectal cancer monitoring | Section 29, Board #7 | Colorectal Cancer Blood Test (Coming Soon) |
About EG BioMed
EG BioMed established its U.S. subsidiary, EG BioMed US Inc., in March 2024 to provide U.S.-patented, advanced blood testing solutions that address the urgent need for early detection of pancreatic cancer—giving patients more treatment options and improving outcomes. The parent company, EG BioMed Co., Ltd., is a spin-off from Taipei Medical University, which is ranked among the world’s Top 250 universities in Clinical and Health.
Our technology has been successfullyapplied to various cancers, includingbreast cancer, pancreatic cancer,lung cancer, and colorectal cancer,with ongoing expansion into additionalcancer screening services.
In February 2025, the EG BioMed US laboratory successfully obtained CLIA certification and Laboratory Developed Test (LDT) authorization for its pancreatic cancer blood test—marking a
significant milestone in our commitment to providing high-quality cancer blood testing services.
Detecting Cancer Early Through ctDNA Methylation
Abnormal Methylated Circulating Tumor DNA (ctDNA) Detection in Blood ctDNA consists of DNA fragments released by cancer cells into the bloodstream. These fragments often carry abnormal methylation of tumor suppressor genes, leading to gene silencing and serving as valuable biomarkers for early cancer detection.
By analyzing the methylation levels ofspecific genes in ctDNA from bloodsamples, we can assess the presenceof cancer cells in the body.
For more information and updates from the meeting, follow EG BioMed on LinkedIn, Facebook, and Instagram, or visit our poster presentations!
Forward-Looking Statements
This press release may contain forward-looking statements, including those regarding EG BioMed’s product development, regulatory strategy, or anticipated clinical benefits. Such statements are based on current expectations and assumptions and involve certain risks and uncertainties. Actual results may differ materially. EG BioMed undertakes no obligation to update any forward-looking statements, except as required by applicable law.
*Not affiliated with or endorsed by AACR.
Contact:
Ruokai Lin
ruokailin@eg-bio.co